Lab Genomics has forged a partnership to distribute Contextual Genomics’ FOLLOW IT liquid biopsy cancer testing.

The FOLLOW IT panel is a multiplex, NGS genomic assay designed for rapid deployment into laboratories.

Under the agreement, Lab Genomics will provide Contextual Genomics’ the next generation sequencing (NGS) based cell-free circulating tumour DNA (ctDNA) cancer genomic testing to patients in Southern California and other parts of the US.

Contextual Genomics CEO Michael Ball said: “The availability of quality-assured cost-effective rapid turnaround time ctDNA testing as a result of this partnership will be of tremendous benefit to many patients suffering from solid tumour cancers, avoiding the need for more invasive tissue biopsies.

“We look forward to working with Lab Genomics to bring this more precise personalised care to cancer patients within their territory.”

The mutation status of cell-free circulating tumour is evaluated by FOLLOW IT. It identifies the somatic mutations that have the maximum potential to impact patient treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lab Genomics founder Leena Dalal said: “At Lab Genomics, our mission is to deliver a suite of unmatched molecular diagnostic services to our customers, to provide preventive, predictive, personalised services.

“This partnership with Contextual Genomics, adding FOLLOW IT liquid biopsy cancer testing for our customers, provides a critical less invasive alternative testing option for cancer patients where tissue biopsy is difficult or not available.

“We look forward to continuing to support the best quality of life possible for all patients and FOLLOW IT will be an important part of our oncology offering.”